- Investing Ideas
- French Pharmaceuticals & Biotech Healthy high growth potential
French Pharmaceuticals & Biotech Healthy high growth potential
Results
3
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
3 companies
MedinCell
Market Cap: €876.2m
Engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.
MEDCL
€24.40
7D
-1.9%
1Y
40.7%
DBV Technologies
Market Cap: €728.0m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.46
7D
-3.3%
1Y
55.5%
ABIVAX Société Anonyme
Market Cap: €9.4b
A clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
ABVX
€100.40
7D
-2.8%
1Y
45.9%